<PAPER>
  <mode2 name="17483118_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Mutagenicity and DNA Adduct Formation by the Urban Air Pollutant 2-Nitrobenzanthrone<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
      <s sid="2">2-Nitrobenzanthrone (2-NBA) has recently been detected in ambient air particulate matter.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="3">Its isomer 3-nitrobenzanthrone (3-NBA) is a potent mutagen and suspected human carcinogen identified in diesel exhaust.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
      <s sid="4">The highest mutagenic activity of 2-NBA tested in Salmonella typhimurium was exhibited in strain TA1538-hSULT1A1 expressing human sulfotransferase (SULT) 1A1.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="5">2-NBA also induced mutations in Chinese hamster lung V79 cells expressing human N-acetyltransferase 2 or SULT1A1, but no mutagenicity was observed in the parental cell line.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="6">DNA adduct formation in vitro was examined in different human cell lines by thin-layer chromatography <sup>32</sup>P-postlabeling.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
      <s sid="7">Whereas 3-NBA formed characteristic DNA adducts in lung A549, liver HepG2, colon HCT116, and breast MCF-7 cells, 2-NBA&#8211;derived DNA adducts were only observed in A549 and HepG2 cells, indicating differences in the bioactivation of each isomer.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="8">The pattern of 2-NBA&#8211;derived DNA adducts in both cell lines consisted of a cluster of up to five adducts.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="9">In HepG2 cells DNA binding by 2-NBA was up to 14-fold lower than by 3-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      <s sid="10">DNA adduct formation of 2-NBA was also investigated in vivo in Wistar rats treated with a single dose of 2, 10, or 100 mg/kg body weight (bw).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
      <s sid="11">No DNA adduct formation was detected at doses of up to 10 mg/kg bw 2-NBA, even though 3-NBA induced DNA adducts at a dose of 2 mg/kg bw.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
      <s sid="12">Only after administration of one high dose of 100 mg/kg bw 2-NBA was a low level of DNA adduct formation detected, and then only in lung tissue.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
      <s sid="13">Density functional theory calculations for both NBAs revealed that the nitrenium ion of the 3-isomer is considerably more stable (&#8764;10 kcal/mol) than that of the 2-isomer, providing a possible explanation for the large differences in DNA adduct formation and mutagenicity between 2- and 3-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
      <s sid="14">Numerous epidemiological studies have shown increased mortality and morbidity from respiratory and cardiovascular diseases due to ambient air pollution (<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">Farmer et al., 2003</xref>; <xref class="xref-bibr" href="#ref-62" rid="xref-ref-62-1">Vineis et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
      <s sid="15">A complex variety of genotoxins in ambient air pollution has been detected (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-1">Kyrtopoulos et al., 2001</xref>), and high exposures are associated with an increased risk of cancer.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
      <s sid="16">Amongst these are nitropolycyclic aromatic hydrocarbons (nitro-PAHs) which may be present on particulate matter from direct sources, such as diesel and gasoline exhaust (<xref class="xref-bibr" href="#ref-59" rid="xref-ref-59-1">Tokiwa and Ohnishi, 1986</xref>) and may be produced from gas-phase reactions of PAHs with oxides of nitrogen, with subsequent partitioning to the particulate phase (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">Bamford et al., 2003</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
      <s sid="17">Both their long persistence in the environment and the mutagenic and carcinogenic properties of certain nitro-PAHs compared has led to considerable interest in assessing their potential risk to humans (Environmental Protection Agency [EPA], 2002; International Agency for Research on Cancer [IARC], 1989; International Programme on Chemical Safety [IPCS], 2003; <xref class="xref-bibr" href="#ref-60" rid="xref-ref-60-1">Tokiwa et al., 1993</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
      <s sid="18">Although environmental levels are lower compared to unsubstituted PAHs (IPCS, 2003), it has become clear that certain nitro-PAHs exhibit high direct-acting mutagenic potency in bacterial bioassays and in forward mutation assays based on mammalian cells (<xref class="xref-bibr" href="#ref-49" rid="xref-ref-49-1">Purohit and Basu, 2000</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
      <s sid="19">The aromatic nitroketone 3-nitrobenzanthrone (<xref class="xref-fig" href="#F1" rid="xref-fig-1-1">Fig. 1B</xref>; 3-NBA, 3-nitro-7H-benz[de]anthracen-7-one) is one of the most potent mutagens and a potential human carcinogen identified in diesel exhaust and ambient air particulate matter (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">Arlt, 2005</xref>; <xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">Enya et al., 1997</xref>; <xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-1">Nagy et al., 2005a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
      <s sid="20">As a likely consequence of atmospheric washout, 3-NBA has also been detected in rain water and surface soil (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-2">Arlt, 2005</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
      <s sid="21">The uptake of 3-NBA in humans has been demonstrated by the detection of 3-aminobenzanthrone (3-ABA), a major metabolite of 3-NBA, in the urine of workers occupationally exposed to diesel emissions (<xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-1">Seidel et al., 2002</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
      <s sid="22">There is clear evidence that 3-NBA is a genotoxic mutagen forming DNA adducts after metabolic activation through reduction of the nitro group (<xref class="xref-fig" href="#F1" rid="xref-fig-1-2">Fig. 1B</xref>) (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">Arlt et al., 2001a</xref>, <xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">2003c</xref>, 2005, 2006; <xref class="xref-bibr" href="#ref-53" rid="xref-ref-53-1">Stiborova et al., 2006</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
      <s sid="23">The predominant DNA adducts detected in vivo in rodents are 2-(2&#8242;-deoxyguanosin-N<sup>2</sup>-yl)-3-aminobenzanthrone and N-(2&#8242;-deoxyguanosin-8-yl)-3-aminobenzanthrone (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">Arlt et al., 2006</xref>) and are most probably responsible for the GC to TA transversion mutations induced by 3-NBA in vivo (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">Arlt et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
      <s sid="24">These DNA adducts not only represent premutagenic lesions in DNA but may also be of primary importance for tumor development in target tissues (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">Bieler et al., 2005</xref>, <xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">2007</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
      <s sid="25">3-NBA is a potent carcinogen after intratracheal instillation in rats, inducing mainly squamous cell carcinoma in lung (<xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-2">Nagy et al., 2005a</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
      <s sid="26">2-Nitrobenzanthrone (2-NBA, 2-nitro-7H-benz[de]anthracen-7-one), an isomer of 3-NBA, can be formed under atmospheric conditions from benzanthrone, a widely distributed contaminant in the atmosphere, and nitrogen oxides (<xref class="xref-fig" href="#F1" rid="xref-fig-1-3">Fig. 1A</xref>) (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-2">Enya et al., 1997</xref>, <xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">1998a</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-1">Suzuki et al., 1997</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
      <s sid="27">It has been detected in ambient air samples in the United States and Japan (<xref class="xref-bibr" href="#ref-48" rid="xref-ref-48-1">Phousongphouang and Arey, 2003</xref>; <xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-1">Tang et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
      <s sid="28">It has been suggested that 2-NBA might be formed more specifically by atmospheric processes while 3-NBA seems to be formed preferentially by combustion processes, such as in a diesel engine (<xref class="xref-bibr" href="#ref-48" rid="xref-ref-48-2">Phousongphouang and Arey, 2003</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
      <s sid="29">In one air sample, atmospheric levels of 2- and 3-NBA were 495 and 6.8 pg/m<sup>3</sup>, respectively, with a ratio of 2-NBA/3-NBA of around 70 (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-2">Tang et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
      <s sid="30">Although little is yet known about the toxicity of 2-NBA, it has been shown to have strand-breaking activity in the comet assay and to form DNA adducts in human A549 lung cells and in vivo in rats, as measured by high-performance liquid chromatography (HPLC) <sup>32</sup>P-postlabeling (<xref class="xref-bibr" href="#ref-45" rid="xref-ref-45-1">Nagy et al., 2005b</xref>, <xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-1">2007</xref>).<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      <s sid="31">Although the genotoxic potential of 2-NBA in these bioassays is lower than that of 3-NBA, its higher abundance in ambient air urges further investigation to evaluate its potential human health hazard.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
      <s sid="32">The aim of the present study was to determine the mutagenic activity of 2-NBA in bacteria and in mammalian cells, and to examine the metabolism and DNA adduct formation of 2-NBA and its metabolite N-hydroxy-2-aminobenzanthrone (<xref class="xref-fig" href="#F1" rid="xref-fig-1-4">Fig. 1A</xref>; N-OH-2-ABA) in human cells in vitro and in rats in vivo by thin-layer chromatography (TLC) <sup>32</sup>P-postlabeling analysis.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/></s>
      <s sid="33">Human cells and rats were also treated with 3-NBA and N-hydroxy-3-aminobenzanthrone (<xref class="xref-fig" href="#F1" rid="xref-fig-1-5">Fig. 1B</xref>; N-OH-3-ABA) in order to provide a basis for assessing the genotoxic potential of 2-NBA in comparison with its isomer 3-NBA.<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
    </p>
    <SEC>
      <TITLE>MATERIALS AND METHODS</TITLE>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Synthesis of 2-NBA, 3-NBA, N-OH-2-ABA and N-OH-3-ABA.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="34">2-NBA was synthesized as reported (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-2">Suzuki et al., 1997</xref>) and provided by T. Takamura-Enya.<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="35">3-NBA was prepared as described (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">Arlt et al., 2002</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
        <s sid="36">N-OH-2-ABA was prepared by reduction of 2-NBA with hydrazine and Pd/C catalysis, essentially as described previously for N-OH-3-ABA (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">Enya et al., 1998b</xref>; <xref class="xref-bibr" href="#ref-47" rid="xref-ref-47-1">Osborne et al., 2005</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="37">Their authenticities were confirmed by ultraviolet spectroscopy, electrospray mass spectrometry, and high-field proton nuclear magnetic resonance spectroscopy.<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Bacterial strains and mutagenicity experiments.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="38">Various Salmonella typhimurium strains were kindly provided by colleagues: TA1538 and TA98 by B.N. Ames (Berkeley, CA), TA1538/1,8-DNP by D. Wild (Kulmbach, Germany), TA98/1,8-DNP<sub>6</sub> by S. Knasm&#252;ller (Vienna, Austria), and YG1021, YG1024, YG1041, and YG7131 by T. Nohmi (Tokyo, Japan).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="39">Strain TA1538-hSULT1A1 has been described elsewhere (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">Glatt and Meinl, 2004</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="40">Strain YG7131-hSULT1A1 was constructed using the same expression vector (encoding the reference type variant of the protein, *1).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="41">Strains TA1538-hSULT1A1 and YG7131-hSULT1A1 showed similar SULT1A1 (sulfotransferase) protein levels (approximately 0.7&#8211;1.4% of the total cytosolic protein).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
        <s sid="42">Bacteria were grown in Oxoid Broth No. 2 (Oxoid GmbH, Wesel, Germany) overnight at 37&#176;C in the presence of 50 &#956;g/ml ampicillin (TA1538-hSULT1A1 and YG7131-hSULT1A1), 25 &#956;g/ml ampicillin plus 12.5 &#956;g/ml tetracycline (YG1021 and YG1024), 25 &#956;g/ml ampicillin plus 25 &#956;g/ml kanamycin (YG1041), or in the absence of antibiotics (remaining strains).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="43">The cultures were centrifuged, suspended in medium A (1.6 g/l Bacto Nutrient Broth + 5 g/l sodium chloride), adjusted nephelometrically to a titer of 1 to 2 &#215; 10<sup>9</sup> bacteria (colony-forming units)/ml, and kept on ice.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="44">Shortly before use they were centrifuged again and suspended at a fivefold higher density in medium A.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="45">Mutagenicity was determined using a modified version of the liquid-preincubation assay described by <xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-1">Maron and Ames (1983)</xref>.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="46">The bacterial suspension (100 &#956;l) and the test compound (in 10 &#956;l dimethyl sulfoxide [DMSO]) were added sequentially to a glass tube containing 500 &#956;l of 100mM magnesium sulfate.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="47">After incubation for 60 min at 37&#176;C, 2.0 ml of 45&#176;C warm soft agar (5.5 mg/ml agar, 5.5 mg/ml sodium chloride, 50&#956;M biotin, 50&#956;M histidine, 25mM sodium phosphate buffer, pH 7.4) was added, and the mixture was poured onto a Petri dish containing 24 ml of minimal agar (15 mg/ml agar in Vogel&#8211;Bonner E medium with 20 mg/ml glucose).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="48">After incubation for 3 days (TA1538/1,8-DNP) or 2 days (all other strains) in the dark, the colonies (his<sup>+</sup> revertants) were counted.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Mammalian cell lines and mutagenicity experiments.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="49">Isoforms of human N-acetyltransferase (NAT) 2 (*4) and SULT1A1 (*1) were stably expressed in Chinese hamster V79 cells (subline V79MZ) as described elsewhere (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-2">Arlt et al., 2002</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="50">The SULT1A1 protein level of V79MZ-hSULT1A1 cells was similar to that of three human liver samples studied concurrently (<xref class="xref-bibr" href="#ref-41" rid="xref-ref-41-1">Meinl et al., 2006</xref>), whereas the level of NAT2 was 20 times above the highest hepatic levels found among eight subjects (H.R. Glatt, unpublished results).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="51">V79MZ cells were grown in Dulbecco's modified Eagle's medium, supplemented with 5% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 &#956;g/ml).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="52">Cultures were maintained at 37&#176;C in a humidified atmosphere containing 5% CO<sub>2</sub>.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="53">Acquisition of resistance toward 6-thioguanine (involving inactivation of the X-chromosomal hprt gene) was used to study the induction of gene mutations.<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
        <s sid="54">The experimental protocol has been described previously (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">Glatt et al., 1998</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="55">Following the incubation of 1.5 &#215; 10<sup>6</sup> cells in 30 ml of medium for 18 h in a 15-cm Petri dish, the test compound (dissolved in 60 &#956;l DMSO) was added.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="56">After an exposure period of 24 h, the test compound was removed by change of the medium, and cells of some cultures were harvested for determining DNA adduct formation (see below).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Human cell treatment for DNA adduct analysis.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="57">Human A549 (lung carcinoma), HepG2 (hepatocarcinoma), HCT116 (colon carcinoma), and MCF-7 (breast adenocarcinoma) cells were purchased from the European Collection of Cell Cultures (Salisbury, UK).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="58">Cells were grown as adherent monolayers and maintained in Eagle's MEM supplemented with 2mM <span class="sc">L</span>-glutamine, 1mM sodium pyruvate, 1% nonessential amino acids, 10% fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 &#956;g/ml) (<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">Hockley et al., 2006</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="59">All media were purchased from Sigma-Aldrich, UK.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
        <s sid="60">Subculturing was performed every 72 h when the cells were 80% confluent and incubated in a humidified 5% CO<sub>2</sub> atmosphere at 37&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="61">For treatment A549 (1 &#215; 10<sup>6</sup> cells), MCF-7 (2 &#215; 10<sup>6</sup> cells), HCT116 (2.25 &#215; 10<sup>6</sup> cells), and HepG2 cells (4 &#215; 10<sup>6</sup> cells) were seeded in T75 flasks in a total volume of 15 ml (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">Arlt et al., 2001b</xref>; <xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-2">Hockley et al., 2006</xref>) and after 48 h the appropriate concentrations of 2-NBA, 3-NBA, N-OH-2-ABA, or N-OH-3-ABA dissolved in DMSO were added, and incubated for a further 24 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="62">Controls were treated with vehicle, DMSO, only.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="63">All incubations were carried out in duplicate and cells were harvested by trypsinisation and then washed with PBS.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="64">Cell viability was determined as described (<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">Arlt et al., 2003a</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
        <s sid="65">DNA was isolated from cells by phenol extraction essentially as reported previously (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-2">Arlt et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met12" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Animal treatment for DNA adduct analysis.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="66">Female Wistar rats (n = 3 per group) were treated with a single dose of 2, 10, or 100 mg/kg body weight (bw) 2-NBA dissolved in tricaprylin by intraperitoneal (ip) injection.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="67">Additional groups of rats were treated ip with a single dose of 10 mg/kg bw N-OH-2-ABA or N-OH-3-ABA dissolved in DMSO.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="68">For 3-NBA (dissolved in tricaprylin) rats (n = 3) were treated with 2 mg/kg bw as described previously (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">Arlt et al., 2003b</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
        <s sid="69">In a further experiment rats (n = 3) were treated ip with 10 mg/kg bw 2-NBA dissolved in tricaprylin daily for 5 days.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="70">Control rats (n = 3) received vehicle only.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="71">Animals were killed 24 h after treatment.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="72">Five organs (liver, lung, pancreas, colon, and kidney) were removed and stored at &#8722;80&#176;C until DNA isolation by standard phenol/chloroform extraction.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">DNA adduct analysis using the TLC <sup>32</sup>P-postlabeling assay. </h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="73">DNA adducts were measured in each DNA sample using the butanol enrichment version of the <sup>32</sup>P-postlabeling method as described previously (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-3">Arlt et al., 2002</xref>) with minor modifications.<CoreSc1 atype="GSC" type="Met" conceptID="Met13" novelty="None" advantage="None"/></s>
        <s sid="74">Briefly, DNA samples (4 &#956;g) were digested with micrococcal nuclease (120 mU, Sigma) and calf spleen phosphodiesterase (40 mU, Calbiochem, UK), extracted with butanol and labeled as reported.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="75">Chromatographic conditions for TLC on polyethyleneimine-cellulose were D1, 1.0M sodium phosphate, pH 6.0; D3, 4M lithium formate, 7M urea, pH 3.5; D4, 0.8M lithium chloride, 0.5M Tris, 8.5M urea, pH 8.0.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
        <s sid="76">DNA adduct levels (RAL, relative adduct labeling) were calculated from the adduct cpm, the specific activity of [&#947;-<sup>32</sup>P]-adenosine triphosphate, and the amount of DNA (pmol of DNA-P) used.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
        <s sid="77">3-NBA&#8211;derived DNA adducts were identified using authentic standards as described previously (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-2">Arlt et al., 2006</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met14" novelty="None" advantage="None"/></s>
        <s sid="78">Results were expressed as DNA adducts/10<sup>8</sup> nucleotides (nt).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Quantum chemical calculations.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="79">The energy calculations and geometry optimizations were performed with the GAUSSIAN 03 program suite (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-1">Frisch et al., 2003</xref>) utilizing restricted density function theory (DFT).<CoreSc1 atype="GSC" type="Met" conceptID="Met15" novelty="None" advantage="None"/></s>
        <s sid="80">The nonlocal B3LYP functional hybrid method was employed (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">Becke, 1988</xref>, <xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">1993</xref>; <xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-1">Lee et al., 1988</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met16" novelty="None" advantage="None"/></s>
        <s sid="81">The standard 6-31G(d,p) basis set (<xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">Hariharan and Pople, 1973</xref>) was used for the geometry optimization and frequency analysis.<CoreSc1 atype="GSC" type="Met" conceptID="Met17" novelty="None" advantage="None"/></s>
        <s sid="82">The zero-point vibrational energies were scaled according to Wong (0.9804) (<xref class="xref-bibr" href="#ref-63" rid="xref-ref-63-1">Wong, 1996</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met18" novelty="None" advantage="None"/></s>
        <s sid="83">Subsequent single-point energy calculations were performed with the larger 6-311G(2df,p) basis set.<CoreSc1 atype="GSC" type="Met" conceptID="Met19" novelty="None" advantage="None"/></s>
        <s sid="84">The electron affinities were calculated as described by <xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">Foresman and Frisch (1996)</xref> and the bond dissociation energies (BDE) as described previously (<xref class="xref-bibr" href="#ref-50" rid="xref-ref-50-1">Reynisson and Steenken, 2004</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met20" novelty="None" advantage="None"/></s>
        <s sid="85">The effect of the aqueous phase was simulated with Self-Consistent Isodensity Polarized Continuum model (<xref class="xref-bibr" href="#ref-61" rid="xref-ref-61-1">Tomasi et al., 2005</xref>) using the same method as described above except that a slightly smaller 6-31G basis set was used for the geometry optimization and frequency analysis.<CoreSc1 atype="GSC" type="Met" conceptID="Met21" novelty="None" advantage="None"/></s>
        <s sid="86">In all the cases, the molecular species were reoptimized within the applied continuum except for the nitrated (&#8211;NO<sub>2</sub>) derivatives where the structures, optimized in vacuum, were used.<CoreSc1 atype="GSC" type="Met" conceptID="Met22" novelty="None" advantage="None"/></s>
        <s sid="87">The Gibbs free energy was calculated according to the following equation &#916;G<sub>aq</sub> = E<sup>PCM-B3LYP</sup> &#8722; E<sup>B3LYP</sup>.<CoreSc1 atype="GSC" type="Met" conceptID="Met23" novelty="None" advantage="None"/></s>
        <s sid="88">The Natural Population Analysis (NPA) (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">Foster and Weinhold, 1980</xref>) and Mulliken's method (<xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-1">Mulliken, 1962</xref>) were used to calculate the charge densities for the molecular systems at the same level of theory as the single-point energy calculations.<CoreSc1 atype="GSC" type="Met" conceptID="Met24" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>RESULTS</TITLE>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Mutagenicity in Bacteria</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="89">2-NBA was directly mutagenic to the standard Salmonella typhimurium strains TA1538 and TA98 even at low substrate concentrations (<xref class="xref-fig" href="#F2" rid="xref-fig-2-1">Fig. 2</xref>, <xref class="xref-table" href="#T1" rid="xref-table-wrap-1-1">Table 1</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="90">These strains differ by the absence and presence, respectively, of plasmid pKM101, encoding a translesion-synthesis DNA polymerase.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="91">Since the mutagenic activity of 2-NBA was similar in both strains, overexpression of this polymerase does not appear to be important in the fixation of 2-NBA-induced mutations in this system.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="92">Strains lacking endogenous acetyltransferase (OAT), TA1538/1,8-DNP and TA98/1,8-DNP<sub>6</sub>, showed reduced mutagenic responses to 2-NBA (by a factor of approximately three) compared to the parental strains TA1538 and TA98, whereas overexpression of this enzyme (in strain YG1024 compared to TA98, and YG1041 compared to YG1021) had little effect (<xref class="xref-table" href="#T1" rid="xref-table-wrap-1-2">Table 1</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="93">However, expression of another enzyme that could catalyze the formation of reactive esters from N-OH-2-ABA, human SULT1A1, enhanced the mutagenicity 2.8-fold in TA1538 background strains and 60-fold in YG7131 strains.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
        <s sid="94">In the latter strains the nitroreductase gene is disrupted (<xref class="xref-table" href="#T1" rid="xref-table-wrap-1-3">Table 1</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="95">This disruption led to a 200-fold decrease in the mutagenic response to 2-NBA in the absence of human SULT.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="96">The decrease resulting from nitroreductase deficiency was less, but still ninefold, when human SULT1A1 was expressed (<xref class="xref-table" href="#T1" rid="xref-table-wrap-1-4">Table 1</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="97">Plasmid-mediated overexpression of the nitroreductase enhanced the mutagenicity twofold (in strain YG1021 compared to TA98) and fourfold (in YG1041 compared to YG1024).<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Mutagenicity in Mammalian Cells</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-22">
        <s sid="98">2-NBA did not induce gene mutations (determined at the hprt locus) in normal Chinese hamster V79MZ cells, at any concentration used (0.03&#8211;30&#956;M).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="99">However, when either human NAT2 or SULT1A1 was expressed in these cells, a mutagenic effect was observed with 2-NBA even at a concentration of 0.1&#956;M (<xref class="xref-fig" href="#F3" rid="xref-fig-3-1">Fig. 3A</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="100">The concentration&#8211;response curves were similar for both enzymes.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="101">However, the expression level of SULT1A1 in the recombinant cell was similar to that observed in some human tissues (liver and small intestine), whereas the relative expression level of NAT2 was 20 times higher in the cell line.<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-24">
        <s sid="102">In other experiments, the metabolite N-OH-2-ABA was tested for mutagenicity (<xref class="xref-fig" href="#F3" rid="xref-fig-3-2">Fig. 3B</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="103">Unlike 2-NBA, this metabolite was mutagenic in parental V79MZ cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="104">Expression of human conjugating enzymes enhanced this mutagenicity.<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="105">The enhancement was stronger with NAT2 than with SULT1A1.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Metabolic Activation and DNA Adduct Formation in Mammalian Cells Expressing Recombinant Human NAT2 or SULT1A1</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-25">
        <s sid="106">For DNA adduct analysis parental and recombinant V79 cells were treated with 3&#956;M 2-NBA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
        <s sid="107">Multiple DNA adducts were detected in V79MZ-derived cells expressing human NAT2 or SULT1A1, whereas no DNA adducts were observed in the parental cell line V79MZ (<xref class="xref-fig" href="#F4" rid="xref-fig-4-1">Fig. 4A</xref>), suggesting that DNA adduct formation is directly linked to the observed mutagenicity in these cells (see above).<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="108">The DNA adduct pattern consisted of a cluster of up to seven adducts, the major ones were also detected in human A549 and HepG2 cells treated with 2-NBA (see below; compare <xref class="xref-fig" href="#F6" rid="xref-fig-6-1">Fig. 6</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="109">DNA binding in V79MZ-derived cells expressing human NAT2 (140 adducts/10<sup>8</sup> nt) was slightly higher than those expressing human SULT1A1 (108 adducts/10<sup>8</sup> nt) (<xref class="xref-fig" href="#F5" rid="xref-fig-5-1">Fig. 5A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-29">
        <s sid="110">DNA adduct formation was also investigated in V79 cells after treatment with N-OH-2-ABA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
        <s sid="111">At 0.1&#956;M multiple DNA adducts were detected in V79MZ-derived cells expressing human NAT2 or SULT1A1 similar to those observed in parental V79MZ cells treated with 2-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="112">Spot 1a (<xref class="xref-fig" href="#F4" rid="xref-fig-4-2">Figs. 4B</xref> and <xref class="xref-fig" href="#F4" rid="xref-fig-4-3">4C</xref>) was the most abundant DNA adduct found; in the parental cell line V79MZ spot 1a was the only DNA adduct detected (<xref class="xref-fig" href="#F4" rid="xref-fig-4-4">Fig. 4D</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
        <s sid="113">DNA binding in V79MZ-derived cells expressing human NAT2 or SULT1A1 was up to sevenfold higher than DNA binding in parental V79MZ cells (<xref class="xref-fig" href="#F5" rid="xref-fig-5-2">Fig. 5B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">DNA Adduct Formation in Human Cells</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-30">
        <s sid="114">Human cells (A549, HepG2, HCT116, and MCF-7) treated with 2-NBA, 3-NBA, N-OH-2-ABA, or N-OH-3-ABA were analyzed by TLC <sup>32</sup>P-postlabeling using butanol enrichment.<CoreSc1 atype="GSC" type="Met" conceptID="Met25" novelty="None" advantage="None"/></s>
        <s sid="115">In A549 and HepG2 cells, the DNA adduct pattern induced by 2-NBA consisted of a cluster of up to five adduct spots (adducts 1a&#8211;5a) (<xref class="xref-fig" href="#F6" rid="xref-fig-6-2">Figs. 6</xref>A<sub>a</sub> and 6B<sub>a</sub>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
        <s sid="116">No DNA adducts were detected in control cells (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
        <s sid="117">DNA adduct formation was concentration dependent, with relative adduct levels of 165/10<sup>8</sup> nt and 213/10<sup>8</sup> nt in A549 and HepG2 cells at the highest 2-NBA concentration (5&#956;M) tested, respectively (<xref class="xref-fig" href="#F7" rid="xref-fig-7-1">Fig. 7A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/></s>
        <s sid="118">Similarly, DNA adduct formation was observed in A549 and HepG2 cells treated with 3-NBA (<xref class="xref-fig" href="#F6" rid="xref-fig-6-3">Figs. 6</xref>A<sub>b</sub> and 6B<sub>b</sub>); however, DNA binding by 3-NBA was up to 14-fold higher than by 2-NBA in HepG2 cells (<xref class="xref-fig" href="#F7" rid="xref-fig-7-2">Fig. 7B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="119">Interestingly, no 2-NBA-derived DNA adducts were found in HCT116 and MCF-7 cells (<xref class="xref-fig" href="#F6" rid="xref-fig-6-4">Figs. 6</xref>C<sub>a</sub> and 6D<sub>a</sub>), whereas under the same experimental conditions DNA adduct formation by 3-NBA was observed clearly (<xref class="xref-fig" href="#F6" rid="xref-fig-6-5">Figs. 6</xref>C<sub>b</sub> and 6D<sub>b</sub>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-32">
        <s sid="120">DNA adducts were detected in all human cells treated with N-OH-2-ABA (<xref class="xref-fig" href="#F6" rid="xref-fig-6-6">Fig. 6</xref>A<sub>c</sub>&#8722;D<sub>c</sub>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs11" novelty="None" advantage="None"/></s>
        <s sid="121">The DNA adduct pattern consisted of a cluster of up to five adduct spots (adducts 1a&#8211;5a), adducts 1a, 2a, and 3a being the major ones detected, similar to the adduct pattern observed in 2-NBA&#8211;treated A549 and HepG2 cells (compare <xref class="xref-fig" href="#F6" rid="xref-fig-6-7">Figs. 6</xref>A<sub>a</sub> and 6B<sub>a</sub>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs12" novelty="None" advantage="None"/></s>
        <s sid="122">The extent of DNA binding in the latter cells treated with 2-NBA and N-OH-2-ABA was similar (<xref class="xref-fig" href="#F7" rid="xref-fig-7-3">Fig. 7C</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs13" novelty="None" advantage="None"/></s>
        <s sid="123">The same characteristic DNA adduct pattern was found in all human cells treated with N-OH-3-ABA as that formed by 3-NBA (<xref class="xref-fig" href="#F6" rid="xref-fig-6-8">Fig. 6</xref>A<sub>d</sub>&#8722;D<sub>d</sub>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs14" novelty="None" advantage="None"/></s>
        <s sid="124">However, DNA binding by N-OH-3-ABA in human cells was lower compared with 3-NBA (<xref class="xref-fig" href="#F7" rid="xref-fig-7-4">Figs. 7B</xref> and <xref class="xref-fig" href="#F7" rid="xref-fig-7-5">7C</xref>), whereas the extent of DNA binding by N-OH-2-ABA and N-OH-3-ABA varied markedly between cell lines (<xref class="xref-fig" href="#F7" rid="xref-fig-7-6">Fig. 7C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">DNA Adduct Formation in Rats</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33">
        <s sid="125">The formation of DNA adducts in various organs (liver, lung, pancreas, colon, and kidney) of female Wistar rats treated with 2- or 3-NBA was analyzed using the butanol enrichment version of the TLC <sup>32</sup>P-postlabeling method (<xref class="xref-fig" href="#F8" rid="xref-fig-8-1">Fig. 8</xref>; <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-1">Table 2</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met26" novelty="None" advantage="None"/></s>
        <s sid="126">As shown in <xref class="xref-fig" href="#F8" rid="xref-fig-8-2">Figure 8</xref>C 3-NBA&#8211;specific DNA adduct patterns identical to those found previously (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-2">Arlt et al., 2001a</xref>, <xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-2">2003b</xref>, 2006) were detected in all organs of rats treated with 2 mg/kg bw 3-NBA.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs15" novelty="None" advantage="None"/></s>
        <s sid="127">DNA binding was similar to that found in a study performed previously under the same experimental conditions, although DNA binding in pancreas was approximately threefold lower in the present study (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-3">Arlt et al., 2003b</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
        <s sid="128">The highest DNA binding was observed in kidney with 134 adducts/10<sup>8</sup> nt, followed by lung (89/10<sup>8</sup> nt), colon (87/10<sup>8</sup> nt), and pancreas (84/10<sup>8</sup> nt) (<xref class="xref-table" href="#T2" rid="xref-table-wrap-2-2">Table 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs16" novelty="None" advantage="None"/></s>
        <s sid="129">In contrast, using equal amounts of 2-NBA (2 mg/kg bw; single administration) DNA adducts were not detectable in any of the organs investigated (<xref class="xref-fig" href="#F8" rid="xref-fig-8-3">Fig. 8B</xref>; <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-3">Table 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs17" novelty="None" advantage="None"/></s>
        <s sid="130">No DNA adducts were observed in controls (<xref class="xref-fig" href="#F8" rid="xref-fig-8-4">Fig. 8A</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs18" novelty="None" advantage="None"/></s>
        <s sid="131">Single or repeated (once daily for 5 days) treatment of rats with 10 mg/kg bw 2-NBA also resulted in no DNA adduct formation in any of the organs (<xref class="xref-fig" href="#F8" rid="xref-fig-8-5">Figs. 8D</xref> and <xref class="xref-fig" href="#F8" rid="xref-fig-8-6">8E</xref>; <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-4">Table 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs19" novelty="None" advantage="None"/></s>
        <s sid="132">Only a single treatment with 100 mg/kg bw 2-NBA resulted in the formation of DNA adducts at a low level (5 adducts/10<sup>8</sup> nt) in lung (<xref class="xref-fig" href="#F8" rid="xref-fig-8-7">Fig. 8</xref>F<sub>a</sub>), but not in liver (<xref class="xref-fig" href="#F8" rid="xref-fig-8-8">Fig. 8</xref>F<sub>b</sub>), pancreas, colon, or kidney (<xref class="xref-table" href="#T2" rid="xref-table-wrap-2-5">Table 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs20" novelty="None" advantage="None"/></s>
        <s sid="133">In lung one adduct was detected (<xref class="xref-fig" href="#F8" rid="xref-fig-8-9">Fig. 8</xref>F<sub>a</sub>) and comparative analyses on TLC indicated that it was chromatographically indistinguishable from adduct 2a found in DNA of human cells treated with 2-NBA (compare <xref class="xref-fig" href="#F6" rid="xref-fig-6-9">Fig. 6</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-39">
        <s sid="134">We also examined DNA adducts in female Wistar rats treated with 10 mg/kg bw of the reactive N-hydroxy arylamine metabolites, N-OH-2-ABA and N-OH-3-ABA (<xref class="xref-fig" href="#F9" rid="xref-fig-9-1">Fig. 9</xref>; <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-6">Table 2</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/></s>
        <s sid="135">Characteristic DNA adduct patterns were observed in all organs investigated (liver, lung, pancreas, colon, and kidney) in rats treated with N-OH-3-ABA (<xref class="xref-fig" href="#F9" rid="xref-fig-9-2">Fig. 9C</xref>), identical to those found with the parent nitro-PAH (compare <xref class="xref-fig" href="#F8" rid="xref-fig-8-10">Fig. 8C</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs21" novelty="None" advantage="None"/></s>
        <s sid="136">The highest DNA adduct levels were found in pancreas (430/10<sup>8</sup> nt), followed by lung (312/10<sup>8</sup> nt) and kidney (262/10<sup>8</sup> nt) (<xref class="xref-table" href="#T2" rid="xref-table-wrap-2-7">Table 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs22" novelty="None" advantage="None"/></s>
        <s sid="137">In rats treated with N-OH-2-ABA DNA adducts were found in all organs investigated, although DNA binding was quite low, in the range of 1&#8211;2 adducts/10<sup>8</sup> nt (<xref class="xref-table" href="#T2" rid="xref-table-wrap-2-8">Table 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs23" novelty="None" advantage="None"/></s>
        <s sid="138">The DNA adduct pattern consisted of two adducts in lung, kidney, colon, and pancreas, whereas only one adduct was detectable in liver (<xref class="xref-fig" href="#F9" rid="xref-fig-9-3">Fig. 9B</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs24" novelty="None" advantage="None"/></s>
        <s sid="139">Comparative analyses on TLC with DNA of human cells treated with 2-NBA indicated that these two adducts were chromatographically indistinguishable from adducts 1a and 2a (compare <xref class="xref-fig" href="#F6" rid="xref-fig-6-10">Fig. 6</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Quantum Chemical Calculations</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-41">
        <s sid="140">Previously, it has been shown that the activity of cytosolic nitroreductases toward certain nitro-aromatics is closely related to their single-electron reduction potential (<xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-1">Iwata et al., 1992</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="141">This implies that the rate determining step in this process is the addition of an electron to the organic molecule, in particular its nitroreduction.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
        <s sid="142">Therefore, as shown in <xref class="xref-fig" href="#F1" rid="xref-fig-1-6">Figure 1</xref> we calculated the electron affinity for 2- and 3-NBA which reflects the energy required to reduce them.<CoreSc1 atype="GSC" type="Met" conceptID="Met27" novelty="None" advantage="None"/></s>
        <s sid="143">The electron addition without solvent simulation is exothermic for both isomers with &#8722;42.8 and &#8722;47.6 kcal/mol for 2- and 3-NBA, respectively, the 2-isomer reduction being slightly less exothermic.<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/></s>
        <s sid="144">Taking into account the effects of the aqueous phase the exothermicity increases considerably to &#8722;71.6 and &#8722;77.4 kcal/mol for 2- and 3-NBA, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res33" novelty="None" advantage="None"/></s>
        <s sid="145">This increase is mainly due to the enhanced solubility of the radical anions compared to their parent compounds by &#8764;30 kcal/mol.<CoreSc1 atype="GSC" type="Res" conceptID="Res34" novelty="None" advantage="None"/></s>
        <s sid="146">Both isomers are easily reduced according to these calculations.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-42">
        <s sid="147">The heterolytic BDE for both N-OH-ABAs (<xref class="xref-fig" href="#F1" rid="xref-fig-1-7">Fig. 1</xref>) were also calculated.<CoreSc1 atype="GSC" type="Met" conceptID="Met28" novelty="None" advantage="None"/></s>
        <s sid="148">In vacuum N-OH-2-ABA has &#8764;15 kcal/mol larger BDE than N-OH-3-ABA.<CoreSc1 atype="GSC" type="Res" conceptID="Res35" novelty="None" advantage="None"/></s>
        <s sid="149">To include the effects of the aqueous phase several aspects need to be taken into account since it involves protonation and formation of water as the leaving group.<CoreSc1 atype="GSC" type="Met" conceptID="Met29" novelty="None" advantage="None"/></s>
        <s sid="150">First, the &#916;G<sub>aq</sub> for N-OH-2-ABA is calculated to be &#8722;4.9 kcal/mol and &#8722;4.8 kcal/mol for N-OH-3-ABA; the &#916;G<sub>aq</sub> for their corresponding nitrenium cations are &#8722;48.5 and &#8722;45.6 kcal/mol, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res36" novelty="None" advantage="None"/></s>
        <s sid="151">Second, for the protonation of the OH-moiety H<sup>+</sup> was dehydrated from the aqueous phase.<CoreSc1 atype="GSC" type="Met" conceptID="Met30" novelty="None" advantage="None"/></s>
        <s sid="152">The measured hydration energy of a proton is &#916;G<sub>aq</sub> = &#8722;263.9 kcal/mol (<xref class="xref-bibr" href="#ref-58" rid="xref-ref-58-1">Tissandier et al., 1998</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res37" novelty="None" advantage="None"/></s>
        <s sid="153">Thirdly, a heterolytic bond formation of water occurs and this energy has been experimentally determined as &#8722;390.7 kcal/mol (<xref class="xref-bibr" href="#ref-51" rid="xref-ref-51-1">Schulz et al., 1982</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        <s sid="154">Combining these values, as shown in <xref class="xref-fig" href="#F1" rid="xref-fig-1-8">Figure 1</xref>, both isomers display moderate exothermicities in the 30 to 40 kcal/mol range, i.e., the water elimination is expected to occur and not to be the rate limiting step in this reaction cascade, although the activation energy may play a role.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-43">
        <s sid="155">The relative stability of the nitrenium intermediate appears to be a crucial factor in determining the biological activity of aromatic amines (<xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-1">Kadlubar and Beland, 1985</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="156">Therefore, the relative energies, or energy difference, of the nitrenium cations and their related amino compounds, 2- and 3-ABA, as a comparative model, were calculated.<CoreSc1 atype="GSC" type="Met" conceptID="Met31" novelty="None" advantage="None"/></s>
        <s sid="157">The energy difference between the amino compounds (2- and 3-ABA) was negligible with (0.5 kcal/mol) and without (&#8722;0.2 kcal/mol) solvent simulation (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs25" novelty="None" advantage="None"/></s>
        <s sid="158">However, a large difference was observed for the corresponding nitrenium ions, that of the 3-isomer being much more stable than its 2-isomer by &#8722;9.4 kcal/mol with and &#8722;12.2 kcal/mol without solvent simulation (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res38" novelty="None" advantage="None"/></s>
        <s sid="159">This observation can be explained in terms of the possible conjugation patterns of these two systems as seen in <xref class="xref-fig" href="#F10" rid="xref-fig-10-1">Figure 10</xref>, i.e., the 3-isomer delocalizes the nitrenium ion positive charge in a more effective way than the 2-isomer.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
        <s sid="160">Although the aqueous solution stabilizes the organic cations, reducing to some extent the energy difference between them, the difference is still being considerable, indicating that the nitrenium ion of the 2-isomer is conceivably more reactive than that of the 3-isomer.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-45">
        <s sid="161">The charge distribution was calculated with both the Mulliken and the NPA methods (<xref class="xref-fig" href="#F10" rid="xref-fig-10-2">Fig. 10</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met32" novelty="None" advantage="None"/></s>
        <s sid="162">In order to elucidate the conjugation pattern of the nitrenium cations their charge difference between them and their amino counterparts were derived.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/></s>
        <s sid="163">By performing this subtraction it is possible to locate the atoms that are principally affected by the introduction of a positive charge to the conjugated systems of these rigid and planar molecules.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="164">These results show that the 3-isomer delocalizes the charge more effectively than the 2-isomer, which correlates with the energy calculations.<CoreSc1 atype="GSC" type="Res" conceptID="Res39" novelty="None" advantage="None"/></s>
        <s sid="165">The solvent effects on the charge distribution were insignificant.<CoreSc1 atype="GSC" type="Res" conceptID="Res40" novelty="None" advantage="None"/></s>
        <s sid="166">The fact that both the Mulliken and NPA methods predicted similar changes in charge densities for both isomers investigated supports the reliability of the theoretical methods used.<CoreSc1 atype="GSC" type="Res" conceptID="Res41" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>DISCUSSION</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-46">
        <s sid="167">In a recently published mutagenicity study conducted independently of the present investigations, 2-NBA was around 2000 times less potent than 3-NBA in YG1024, the strain with the highest response toward 3-NBA (<xref class="xref-bibr" href="#ref-56" rid="xref-ref-56-1">Takamura-Enya et al., 2006</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="168">Some strains (TA98, TA98/1,8-DNP<sub>6</sub>, YG1021, and YG1024) have been used as well in our investigation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="169">The largest difference between the studies is seen in strain TA98, with 160 revertants/nmol in the previous study and 3000 revertants/nmol in the present study.<CoreSc1 atype="GSC" type="Res" conceptID="Res42" novelty="None" advantage="None"/></s>
        <s sid="170">The higher response in our study might be due to differences in the assay conditions; we use higher cell densities, a longer liquid-preincubation time, and culture media higher in magnesium sulfate (essential for SULT-expressing strains) than other laboratories.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="171">Interestingly, deficiency of OAT reduced the response, whereas overexpression of this enzyme had practically no influence on the mutagenic activity of 2-NBA in our study.<CoreSc1 atype="GSC" type="Res" conceptID="Res43" novelty="None" advantage="None"/></s>
        <s sid="172">However, previously no influence of OAT deficiency was found, but a marked enhancement of the mutagenicity by overexpression of OAT.<CoreSc1 atype="GSC" type="Res" conceptID="Res44" novelty="None" advantage="None"/></s>
        <s sid="173">Thus, it may be suspected that OAT was more active under the experimental conditions used in the present study.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
        <s sid="174">In both studies, nitroreductase deficiency drastically reduced the mutagenic activity of 2-NBA, whereas overexpression of this enzyme enhanced the activity.<CoreSc1 atype="GSC" type="Res" conceptID="Res45" novelty="None" advantage="None"/></s>
        <s sid="175">Strains expressing a human SULT were used only in our study.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp38" novelty="None" advantage="None"/></s>
        <s sid="176">Expression of SULT1A1 enhanced the mutagenicity of 2-NBA.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs26" novelty="None" advantage="None"/></s>
        <s sid="177">The increase amounted to 2.8-fold using TA1538 as the recipient strain.<CoreSc1 atype="GSC" type="Res" conceptID="Res46" novelty="None" advantage="None"/></s>
        <s sid="178">It was stronger (60-fold) with the nitroreductase-deficient recipient strain YG7131, starting from a much lower background level than in TA1538.<CoreSc1 atype="GSC" type="Res" conceptID="Res47" novelty="None" advantage="None"/></s>
        <s sid="179">Thus, it may be hypothesized that human SULT1A1 was superior to the bacterial acetyltransferase in bioactivation at the low substrate concentrations of N-OH-2-ABA intermediate expected to be present in nitroreductase-deficient strains.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-47">
        <s sid="180">In the present study it is reported for the first time that 2-NBA is capable of inducing gene mutations in mammalian cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res48" novelty="None" advantage="None"/></s>
        <s sid="181">Mutagenicity was not observed in the parental V79MZ cell line, which is used in standard gene mutation, micronucleus and chromosomal aberration tests.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs27" novelty="None" advantage="None"/></s>
        <s sid="182">However, when human NAT2 or SULT1A1 were expressed in this cell line, mutagenicity was detected even at very low concentrations of 2-NBA (0.1&#956;M).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs28" novelty="None" advantage="None"/></s>
        <s sid="183">Unlike 2-NBA, its metabolite N-OH-2-ABA was mutagenic in parental V79MZ cells.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs29" novelty="None" advantage="None"/></s>
        <s sid="184">It is not known whether N-OH-2-ABA or another metabolite produced by the V79MZ cells induced the mutations.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
        <s sid="185">Expression of human NAT2 or SULT1A1 enhanced the mutagenicity of N-OH-2-ABA, in agreement with the effects observed on 2-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res49" novelty="None" advantage="None"/></s>
        <s sid="186">Using TLC <sup>32</sup>P-postlabeling multiple DNA adducts were detectable in V79MZ-derived cells expressing human NAT2 or SULT1A1 treated with 2-NBA (3&#956;M) similar to those observed in human cells (see below), whereas no DNA adducts were found in the parental cell line V79MZ.<CoreSc1 atype="GSC" type="Res" conceptID="Res50" novelty="None" advantage="None"/></s>
        <s sid="187">Higher DNA binding was also observed in V79MZ-derived cells expressing human conjugating enzymes compared to parental cells after treatment with N-OH-2-ABA at the low concentration tested (0.1&#956;M).<CoreSc1 atype="GSC" type="Res" conceptID="Res51" novelty="None" advantage="None"/></s>
        <s sid="188">Thus, expression of human conjugating enzymes NAT2 or SULT1A1 strongly contributes to the genotoxicity and mutagenicity of 2-NBA and N-OH-2-ABA as has been observed previously for 3-NBA (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-4">Arlt et al., 2002</xref>, <xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-2">2003a</xref>, 2005).<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
        <s sid="189">Differences in the modulating effects of the enzymes may be due to variations in the time course of the exposure to N-OH-2-ABA, i.e., initially high with a relatively rapid decrease when N-OH-2-ABA is directly used, lower but more continuous when it is produced by the cells from 2-NBA.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-48">
        <s sid="190">When human cells treated with 2-NBA were used to investigate DNA adduct formation a cluster of up to five adducts were detected using TLC <sup>32</sup>P-postlabeling.<CoreSc1 atype="GSC" type="Res" conceptID="Res52" novelty="None" advantage="None"/></s>
        <s sid="191">All of them were primarily located in a diagonal zone on the TLC plates at approximately 45&#176; to elution directions D3 and D4, similar to DNA adducts formed by 3-NBA (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-3">Arlt et al., 2001a</xref>, <xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-3">2006</xref>; <xref class="xref-bibr" href="#ref-47" rid="xref-ref-47-2">Osborne et al., 2005</xref>) and typical of DNA adducts derived from extracts of airborne particulate matter and diesel exhaust (<xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-1">Gallagher et al., 1991</xref>; <xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">Gupta, 1985</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res53" novelty="None" advantage="None"/></s>
        <s sid="192">In a recent study 2-NBA&#8211;derived DNA adducts were observed in A549 and HepG2 cells by HPLC <sup>32</sup>P-postlabeling (<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-2">Nagy et al., 2007</xref>), at levels about 1/3 and 1/20, respectively, of the levels of 3-NBA&#8211;DNA adduct formation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="193">HepG2 cells have been proven to be a sensitive cell line to examine the genotoxicity of 3-NBA as measured by the induction of single strand breaks (comet assay) and micronuclei (<xref class="xref-bibr" href="#ref-38" rid="xref-ref-38-1">Lamy et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="194">Similarly, in the present study HepG2 cells were the most sensitive human cell line but DNA adduct levels derived from 3-NBA were up to 2.5- and 14-fold higher than by 2-NBA in A549 and HepG2 cells, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res54" novelty="None" advantage="None"/></s>
        <s sid="195">In contrast to 3-NBA, surprisingly, no DNA adduct formation was observed in HCT116 and MCF-7 cells, indicating that these human cells are not metabolically competent to activate 2-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res55" novelty="None" advantage="None"/></s>
        <s sid="196">Since DNA adducts were detected in all human cells exposed to N-OH-2-ABA, it seems that 2-NBA is a poor substrate for nitroreductases in HCT116 and MCF-7 cells.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
        <s sid="197">MCF-7 cells are capable of activating other nitro-PAHs by simple nitroreduction leading to the formation of covalent DNA adducts (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-3">Arlt et al., 2001b</xref>; <xref class="xref-bibr" href="#ref-54" rid="xref-ref-54-1">Sun et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
        <s sid="198">Moreover, it has been shown that DNA binding varied among different mononitropyrene isomers tested, with 4-nitropyrene binding to DNA in MCF-7 cells to a greater extent than 1- and 2-nitropyrene (<xref class="xref-bibr" href="#ref-54" rid="xref-ref-54-2">Sun et al., 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="199">Thus, it remains to be investigated which enzyme(s) are responsible for the reduction and subsequent metabolic activation of 3-NBA, but not 2-NBA, in HCT116 and MCF-7 cells.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
        <s sid="200">Nitroreduction for 3-NBA is primarily catalyzed by cytosolic nitroreductases such as NQO1 (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">Arlt et al., 2005</xref>; <xref class="xref-bibr" href="#ref-53" rid="xref-ref-53-2">Stiborova et al., 2006</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="201">Therefore, further studies will focus on the ability of human NQO1 to bioactivate 2-NBA.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
        <s sid="202">In addition, investigations on the expression of cytosolic and microsomal reductases in A549, HepG2, HCT116, and MCF-7 cells after exposure to 2- and 3-NBA may help to explain these findings.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-49">
        <s sid="203">During the preparation of this manuscript, others investigated DNA adduct formation by 2-NBA in vivo (<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-3">Nagy et al., 2007</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="204">DNA adduct formation in F344 rats after a single intratracheal instillation of 5 mg/kg bw 2-NBA was examined by HPLC <sup>32</sup>P-postlabeling.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="205">Several peaks on the HPLC related to 2-NBA&#8211;derived DNA adduct formation were found at an overall level approximately 80% of that formed by 3-NBA.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="206">In contrast, in the present study we did not detect DNA adduct formation at doses of up to 10 mg/kg bw 2-NBA after intraperitoneal treatment, after either single or repeated administration.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs30" novelty="None" advantage="None"/></s>
        <s sid="207">Only after administration of one high dose of 100 mg/kg bw 2-NBA was a low level of DNA adduct formation detected, and then only in lung tissue.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs31" novelty="None" advantage="None"/></s>
        <s sid="208">In the light of the detection of 2-NBA&#8211;derived DNA adducts in vivo at lower doses by Nagy and coworkers we would have expected to observe DNA adduct formation in the present study.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="209">It should be noted that in the two studies different strains of rats were used (Wistar vs. F344 rats), different routes of administration were applied (intraperitoneal vs. intratracheal administration), and DNA adducts were analyzed in different ways (TLC vs. HPLC <sup>32</sup>P-postlabeling), but whether these or other factors account for the difference in detection of 2-NBA&#8211;derived DNA adducts between the two studies is unclear, and will require further investigation.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot7" novelty="None" advantage="None"/></s>
        <s sid="210">Previously we found that 3-NBA characteristic DNA adducts were detectable by TLC <sup>32</sup>P-postlabeling independently of the route of administration (oral, intraperitoneal, and intratracheal treatment), although DNA binding varied in different tissues (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-4">Arlt et al., 2001a</xref>, <xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-4">2003b</xref>; <xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-2">Bieler et al., 2005</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="211">Moreover, for 3-NBA the same characteristic DNA adducts were observed by HPLC <sup>32</sup>P-postlabeling using different routes of administration (Nagy et al., 2005a, 2006), although TLC <sup>32</sup>P-postlabeling seems to be more sensitive (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-2">Bieler et al., 2007</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="212">Since DNA adducts were observed in vivo for 3-NBA under the same experimental conditions in the present study it seems that, similar to the observations made in HCT116 and MCF-7 cells described above, 2-NBA is also a poorer substrate for nitroreductases in vivo, at least in Wistar rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con11" novelty="None" advantage="None"/></s>
        <s sid="213">Furthermore, although we detected DNA adduct formation in rats treated with N-OH-2-ABA, DNA binding was much lower than that of N-OH-3-ABA, suggesting that N-OH-2-ABA may also be a poorer substrate for NATs and SULTs in vivo in rats, and/or is readily metabolized to 2-ABA, a possible detoxification pathway.<CoreSc1 atype="GSC" type="Con" conceptID="Con12" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-50">
        <s sid="214">Physicochemical values have been used to estimate structure-related biological activities such as mutagenicity and carcinogenicity of different isomeric compounds (Borosky, 2007; <xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">Hatch et al., 2001</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="215">Using a semiempirical quantum mechanical approach a recent study indicated that the mutagenicity of mono-nitrated benzanthrones, including 1-, 2-, 3-, 9-, and 11-NBA, depends on the reduction potential and geometry of the nitro group attached to benzanthrone, although the differences in particular for 2- and 3-NBA were small (<xref class="xref-bibr" href="#ref-56" rid="xref-ref-56-2">Takamura-Enya et al., 2006</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="216">It is also noteworthy that no differences in hydrophobicity were observed among these NBA isomers, indicating that penetration into cell membranes is expected to be similar, and therefore would not be a critical determinant for their mutagenicity or DNA adduct forming potential.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="217">Metabolic activation of nitro-PAHs involves the formation of highly reactive arylnitrenium ions capable of reacting with DNA to form covalent DNA adducts.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="218">Thus, variations in the structures of the aryl moieties of 2- and 3-NBA may have profound effects on the rates of formation and/or the reactivity of their nitrenium ions (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-1">Ford and Herman, 1992</xref>) and, consequently, on their DNA adduct forming potential and mutagenicity.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-51">
        <s sid="219">DFT is a widely applicable and robust method to calculate thermochemical parameters and charge distribution in molecular systems (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">Borosky, 2007</xref>; <xref class="xref-bibr" href="#ref-50" rid="xref-ref-50-2">Reynisson and Steenken, 2004</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="220">Recently, it was shown that among a large group of aromatic and heterocyclic aromatic amines investigated, derivatives with the highest electron density on the exocyclic nitrogen, i.e., the most stable species, were the most mutagenic ones (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-2">Borosky, 2007</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="221">Using the DFT method we observed quite large differences in the energetics of the nitrenium ions derived from 2- and 3-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res56" novelty="None" advantage="None"/></s>
        <s sid="222">Moreover, we found that the 3-isomer delocalizes the positive charge more effectively than the 2-isomer.<CoreSc1 atype="GSC" type="Res" conceptID="Res57" novelty="None" advantage="None"/></s>
        <s sid="223">This could mean that the greater stability of the nitrenium ion of 3-NBA provides it with more time to reach the nucleus, react with DNA and form larger amounts of DNA adducts than the nitrenium ion of 2-NBA.<CoreSc1 atype="GSC" type="Con" conceptID="Con13" novelty="None" advantage="None"/></s>
        <s sid="224">The latter may react more efficiently with cellular macromolecules in the immediate vicinity of its site of formation in the cytoplasm.<CoreSc1 atype="GSC" type="Con" conceptID="Con14" novelty="None" advantage="None"/></s>
        <s sid="225">However, other factors besides the stability of the nitrenium ions may play a role in determining the extent of DNA adduct formation.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-52">
        <s sid="226">In summary, we found that 2-NBA is mutagenic in bacteria and mammalian short-term assays.<CoreSc1 atype="GSC" type="Con" conceptID="Con15" novelty="None" advantage="None"/></s>
        <s sid="227">In contrast to 3-NBA, 2-NBA formed DNA adducts only in some of the human cell lines studied, indicating that differences occur in the metabolic activation pathway of each isomers.<CoreSc1 atype="GSC" type="Res" conceptID="Res58" novelty="None" advantage="None"/></s>
        <s sid="228">Moreover, DNA binding by 2-NBA was generally substantially lower than by 3-NBA.<CoreSc1 atype="GSC" type="Res" conceptID="Res59" novelty="None" advantage="None"/></s>
        <s sid="229">In contrast to a recent report we found no evidence of 2-NBA&#8211;derived DNA adduct formation in vivo in rats at comparable doses, an observation which certainly requires further investigation.<CoreSc1 atype="GSC" type="Res" conceptID="Res60" novelty="None" advantage="None"/></s>
        <s sid="230">Using authentic 2-NBA&#8211;DNA adduct standards in the future may be one step toward resolving these discrepancies.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot9" novelty="None" advantage="None"/></s>
        <s sid="231">Structural calculations showed that physiochemical properties, or more likely a combination of both physiochemical and enzymatic properties, related to 2- and 3-NBA activation may account for their large differences in mutagenicity and DNA adduct formation.<CoreSc1 atype="GSC" type="Con" conceptID="Con16" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-53">
        <s sid="232">We thank C. Churchill, C. Gumz, and A. Katschak for excellent technical assistance.</s>
        <s sid="233">This work was financially supported by Cancer Research UK and in part by the Federal Ministry of Education and Research of Germany (grant 0311243 to H.R. Glatt).</s>
        <s sid="234">V.M. Arlt, G. Gamboa da Costa, and D.H. Phillips are partners of Environmental Cancer Risk, Nutrition and Individual Susceptibility, a network of excellence operating within the European Union 6th Framework, Priority 5: &#8220;Food Quality and Safety&#8221; (Contract No. 513943).</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>